As Nektar Therapeutics (NKTR) Share Price Rose, Rhenman & Partners Asset Management Ab Has Lifted Stake by $19.69 Million

September 16, 2018 - By Mark Babin

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.13 in Q2 2018. Its down 0.30, from 1.43 in 2018Q1. It worsened, as 54 investors sold NKTR shares while 100 reduced holdings. 82 funds opened positions while 92 raised stakes. 157.21 million shares or 2.48% more from 153.40 million shares in 2018Q1 were reported. Tradewinds Management Limited Liability Corporation reported 0% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Amp Invsts has 36,115 shares. Principal Fin Group reported 0.01% in Nektar Therapeutics (NASDAQ:NKTR). D E Shaw stated it has 0.02% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Ls Ltd Liability holds 0.02% or 8,077 shares. Numerixs Inv Techs reported 0.16% stake. Voya Invest Mgmt Llc holds 0.01% or 92,436 shares in its portfolio. 211,200 were reported by Quantitative Inv Mngmt Ltd Llc. Parkside Fin National Bank & Trust Tru accumulated 15 shares or 0% of the stock. Artal Gru Sa accumulated 0.93% or 900,000 shares. 91,675 were accumulated by Hap Trading Ltd Liability. Ameriprise reported 0% in Nektar Therapeutics (NASDAQ:NKTR). Perceptive Advsr Ltd Company has 6,057 shares. 241,922 were accumulated by Sabby Mgmt Ltd Liability Corp. Tiaa Cref Mngmt Ltd Liability Company has invested 0.01% in Nektar Therapeutics (NASDAQ:NKTR).

Since April 5, 2018, it had 1 buy, and 28 selling transactions for $65.54 million activity. $286,445 worth of stock was sold by Doberstein Stephen K on Wednesday, May 16. The insider WINGER DENNIS L sold $1.80M. $298,203 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by Thomsen Jillian B.. Hora Maninder sold 29,498 shares worth $3.03 million. $551,600 worth of Nektar Therapeutics (NASDAQ:NKTR) was sold by CHESS ROBERT. Lingnau Lutz also sold $3.05M worth of Nektar Therapeutics (NASDAQ:NKTR) on Thursday, April 5.

Rhenman & Partners Asset Management Ab increased its stake in Nektar Therapeutics (NKTR) by 197.72% based on its latest 2018Q2 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 410,194 shares as the company’s stock rose 17.51% with the market. The institutional investor held 617,652 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $30.16 million, up from 207,458 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Nektar Therapeutics for a number of months, seems to be bullish on the $10.22 billion market cap company. The stock decreased 4.28% or $2.65 during the last trading session, reaching $59.25. About 2.09M shares traded. Nektar Therapeutics (NASDAQ:NKTR) has risen 187.03% since September 16, 2017 and is uptrending. It has outperformed by 171.41% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $977.11M US Long portfolio, decreased its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 17,000 shares to 17,000 shares, valued at $5.87M in 2018Q2, according to the filing. It also reduced its holding in Xencor Inc (NASDAQ:XNCR) by 83,557 shares in the quarter, leaving it with 216,443 shares, and cut its stake in Glaukos Corp.

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Seekingalpha.com which released: “Nektar: A Rare Opportunity For Long-Term Investors” on September 04, 2018, also Seekingalpha.com with their article: “Healthcare And Biotechnology Dashboard – Update” published on September 11, 2018, Nasdaq.com published: “Here’s Why Nektar Therapeutics Jumped 26.4% in August” on September 06, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Seekingalpha.com and their article: “An Early Look At Nektar And Bristol-Myers Squibb’s First Combination Phase 3 Trial” published on September 11, 2018 as well as Seekingalpha.com‘s news article titled: “Nektar Therapeutics Offers A High-Potential But Controversial Pipeline” with publication date: August 29, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 8 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 7 have Buy rating, 0 Sell and 1 Hold. Therefore 88% are positive. Nektar Therapeutics has $125 highest and $54 lowest target. $96.43’s average target is 62.75% above currents $59.25 stock price. Nektar Therapeutics had 12 analyst reports since March 29, 2018 according to SRatingsIntel. The rating was maintained by Mizuho with “Buy” on Friday, April 6. The stock has “Buy” rating by Mizuho on Thursday, March 29. The rating was maintained by Canaccord Genuity with “Buy” on Tuesday, June 5. The company was downgraded on Monday, June 11 by H.C. Wainwright. JP Morgan maintained it with “Overweight” rating and $78 target in Monday, June 4 report. The stock of Nektar Therapeutics (NASDAQ:NKTR) earned “Buy” rating by Canaccord Genuity on Friday, May 11. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Monday, June 4 by Cowen & Co. The stock has “Buy” rating by H.C. Wainwright on Monday, April 2. On Friday, April 13 the stock rating was maintained by PiperJaffray with “Overweight”. The stock has “Buy” rating by Cowen & Co on Monday, April 9.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.